The long-term inhibition of the endogenous DPP-4 enzymes with sitagliptin can meaningfully delay some forms of AD pathology, including Aβ deposition, when administered early in the disease course of a transgenic mouse model of AD [150]. Here, DPP4 is linked to Alzheimer disease.